Long-term Clinical Outcomes After Retinal Artery Occlusion
ConditionRetinal Artery Occlusion
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorChonnam National University Hospital
About this trial
Retinal artery occlusion (RAO) is a rare but vision-threatening vascular disorder that is commonly caused by embolic events originating from the heart or carotid arteries. Patients with RAO are known to have an increased risk of subsequent cardiovascular and cerebrovascular events, including ischemic stroke and myocardial infarction. However, long-term outcomes and optimal medical treatment strategies for these patients remain insufficiently characterized.
The purpose of this nationwide population-based study is to investigate the incidence of long-term cardiovascular and cerebrovascular outcomes in patients diagnosed with retinal artery occlusion using the Korean National Health Insurance Service (NHIS) database. In addition, the study aims to evaluate the impact of various medical therapies, including antiplatelet agents, anticoagulants, and statins, on long-term clinical outcomes.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients newly diagnosed with retinal artery occlusion
Disqualifiers
Patients with a prior diagnosis of retinal artery occlusion before the study period.
Patients diagnosed with giant cell arteritis.
Trial population
Patients newly diagnosed with retinal artery occlusion (RAO) between 2010 and 2024 identified from the Korean National Health Insurance Service (NHIS) database.
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
retinal artery occlusion
Other interventiontreatment for retinal artery occlusion
Treatment groups
15,000 Participants
are divided into 2 treatment groupsGroup A: Patients who underwent retinal artery occlusion1 intervention
Group B: Matched cohort0 interventions
Trial outcomes
Primary outcomes
1
Occurrence of MACCE
major adverse cardiovascular and cerebrovascular event
Time frame
up to 5 yearsSecondary outcomes
1
Occurrence of all-cause death
Death from any causes
Time frame
up to 5 years2
Occurrence of cardiac death
Death from cardiac causes
Time frame
up to 5 years3
Occurrence of myocardial infarction
Myocarrdial infarction
Time frame
up to 5 years4
Occurrence of revascularization
Percutaneous coronary intervention or coronary artery bypass grafting
Time frame
up to 5 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov